Last reviewed · How we verify
Pregabalin and Oxcarbazepine
Pregabalin and Oxcarbazepine is a Anticonvulsant combination; Gabapentinoid and aromatic antiepileptic drug Small molecule drug developed by Ju Seok Ryu. It is currently FDA-approved for Epilepsy/seizure disorders, Neuropathic pain, Postherpetic neuralgia. Also known as: Lyrica and Oxcarb.
This combination product uses pregabalin to modulate calcium channels and reduce neurotransmitter release, while oxcarbazepine blocks sodium channels to stabilize neuronal membranes and reduce seizure activity.
This combination product uses pregabalin to modulate calcium channels and reduce neurotransmitter release, while oxcarbazepine blocks sodium channels to stabilize neuronal membranes and reduce seizure activity. Used for Epilepsy/seizure disorders, Neuropathic pain, Postherpetic neuralgia.
At a glance
| Generic name | Pregabalin and Oxcarbazepine |
|---|---|
| Also known as | Lyrica and Oxcarb |
| Sponsor | Ju Seok Ryu |
| Drug class | Anticonvulsant combination; Gabapentinoid and aromatic antiepileptic drug |
| Target | Alpha-2-delta calcium channel subunit (pregabalin); voltage-gated sodium channels (oxcarbazepine) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels, reducing calcium influx and decreasing the release of excitatory neurotransmitters. Oxcarbazepine blocks voltage-dependent sodium channels, stabilizing the inactive state of the channel and reducing repetitive neuronal firing. Together, these complementary mechanisms provide enhanced anticonvulsant and neuropathic pain relief effects.
Approved indications
- Epilepsy/seizure disorders
- Neuropathic pain
- Postherpetic neuralgia
Common side effects
- Dizziness
- Somnolence
- Ataxia
- Hyponatremia
- Headache
- Weight gain
Key clinical trials
- A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice (PHASE4)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Symptom Based Treatment of Neuropathic Pain (PHASE4)
- Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database
- Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pregabalin and Oxcarbazepine CI brief — competitive landscape report
- Pregabalin and Oxcarbazepine updates RSS · CI watch RSS
- Ju Seok Ryu portfolio CI
Frequently asked questions about Pregabalin and Oxcarbazepine
What is Pregabalin and Oxcarbazepine?
How does Pregabalin and Oxcarbazepine work?
What is Pregabalin and Oxcarbazepine used for?
Who makes Pregabalin and Oxcarbazepine?
Is Pregabalin and Oxcarbazepine also known as anything else?
What drug class is Pregabalin and Oxcarbazepine in?
What development phase is Pregabalin and Oxcarbazepine in?
What are the side effects of Pregabalin and Oxcarbazepine?
What does Pregabalin and Oxcarbazepine target?
Related
- Drug class: All Anticonvulsant combination; Gabapentinoid and aromatic antiepileptic drug drugs
- Target: All drugs targeting Alpha-2-delta calcium channel subunit (pregabalin); voltage-gated sodium channels (oxcarbazepine)
- Manufacturer: Ju Seok Ryu — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Epilepsy/seizure disorders
- Indication: Drugs for Neuropathic pain
- Indication: Drugs for Postherpetic neuralgia
- Also known as: Lyrica and Oxcarb
- Compare: Pregabalin and Oxcarbazepine vs similar drugs
- Pricing: Pregabalin and Oxcarbazepine cost, discount & access